Pharming Group Exceeds 2025 Revenue Guidance, Announces Investor Day for Pipeline and 2026 Outlook
Summary
Pharming Group N.V. reported preliminary 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance, and announced a virtual Investor Day on February 3, 2026, to discuss pipeline advancements and 2026 financial guidance.
Key Events
-
Preliminary 2025 Revenue Exceeds Guidance
Pharming Group reported preliminary, unaudited 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance range of $365 million to $375 million.
-
Strong Commercial Growth
The company achieved approximately 27% revenue growth in 2025 compared to 2024, driven by continued demand for RUCONEST® and increased patient uptake for Joenja® in the U.S. and internationally.
-
Operating Expenses Within Range
Full-year 2025 operating expenses are expected to be within the previously communicated range of $304 million to $308 million, demonstrating cost discipline.
-
Investor Day Announcement
Pharming will host a virtual Investor Day on February 3, 2026, to provide a comprehensive update on its advancing clinical pipeline, including leniolisib and KL1333, and to present its 2026 financial guidance.
Analysis
Pharming Group's preliminary 2025 revenue exceeding its previously raised guidance signals strong commercial performance, particularly for RUCONEST® and Joenja®. This positive momentum, coupled with disciplined operating expenses, provides a solid foundation for 2026. The upcoming Investor Day is a key event for investors, as it will offer a comprehensive update on the company's clinical pipeline, including leniolisib and KL1333, and provide crucial 2026 financial guidance. This event will be critical for understanding the company's future growth drivers and strategic direction.
At the time of this filing, PHAR was trading at $17.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $7.50 to $18.30. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.